Wells Fargo Downgrades Integra Lifesciences to Equal-Weight, Lowers Price Target to $25
Wells Fargo Downgrades Integra Lifesciences to Equal-Weight, Lowers Price Target to $25
富國銀行將Integra Lifesciences的評級下調至同等權重,將目標股價下調至25美元
Wells Fargo analyst Vik Chopra downgrades Integra Lifesciences (NASDAQ:IART) from Overweight to Equal-Weight and lowers the price target from $45 to $25.
富國銀行分析師維克·喬普拉將Integra Lifesciences(納斯達克股票代碼:IART)的評級從增持下調至同等,並將目標股價從45美元下調至25美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。